Donate
Australian & New Zealand Childrens Haematology/Oncology Group

ANZCHOG Children’s Cancer Clinical Trials Repository

Study Title
Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy
Protocol ID
ALLELE
Disease (Sub Disease)
EBV post transplant
Diagnosis Stage
Refractory
Location
VIC, WA
Sponsor
Atara Biotherapeutics
Trial Status
Open
Sites
Perth Children's Hospital
Royal Children's Hospital
Study Type
Treatment
Phase
Phase 3
Age Eligibility
no limits
International registry ID's
NCT03394365
Back to Registry
Study Title Multicenter Open Label Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy
Protocol ID ALLELE
Disease (Sub Disease) EBV post transplant
Diagnosis Stage Refractory
Location VIC / WA
Sponsor Atara Biotherapeutics
Links https://clinicaltrials.gov/ct2/show/NCT03394365
Trial Status Open
Trial Open Date 29/12/2017
Sites Perth Children's Hospital / Royal Children's Hospital
Study Type Treatment
Phase Phase 3
Age Eligibility no limits
International registry ID's NCT03394365